OrbiMed

量身定制的融资方案和全球团队，帮助创建世界一流的生物医疗公司。

从生物制药到医疗器械、数字健康、诊断和医疗服务，奥博资本致力于在全球范围内寻找能够使人类生活得更健康和更长久的创新项目。

我们深耕全球医疗保健行业投资二十余载：从初创私营公司到大型跨国企业。我们的团队由130余名杰出专业人士组成，其专业背景覆盖科学、医学和投资等领域。奥博资本在全球范围内管理资产逾170亿美元。

我们如何投资

了解我们的医疗创新公司

Messenger RNA targeting to create life-saving therapeutics

ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.

Learn More

Pushing targeted oncology drug discovery to new heights

Treeline Biosciences is pursuing molecular targets in oncology that are validated but difficult to drug, leveraging its four pillars of drug discovery: mechanistic biology, medicinal chemistry, computational science, and structural biology and protein science.

Learn More

Revolutionizing Cancer Care

With a primary focus on cancer, Caris has built a market-leading portfolio of precision medicine tools that have helped more than half a million cancer patients worldwide. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease.

Learn More

Redefining Immunology and Inflammation with Precision

Mirador Therapeutics envisions a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and better development accuracy.

Learn More

A Global Leader in Antibody and ADC Oncology Therapies

Biokin is a clinical-stage company developing innovative ADCs, bi-specific, and multi-specific antibodies for the treatment of cancers. By targeting multiple signaling pathways, Biokin is seeking to overcome the insufficient anti-tumor responses typical of existing mono-antibody therapies.

Learn More

Taking a leading approach to tackle the complexities of cancer

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company’s pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs).

Learn More

查看全部